

De wisselwerking tussen edoxaban en tamoxifen behandeling bij vrouwen met borstkanker

Gepubliceerd: 30-09-2019 Laatste bijgewerkt: 18-08-2022

There is a minimal interaction between edoxaban and tamoxifen and it can safely be used concomitantly

Ethische beoordeling	Positief advies
Status	Werving gestart
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON23145

Bron

Nationaal Trial Register

Verkorte titel

PHIX-IT study

Aandoening

Patients with oestrogen receptor positive breast cancer who are scheduled for adjuvant or palliative tamoxifen treatment

Ondersteuning

Primaire sponsor: Daiichi Sankyo

Overige ondersteuning: Daiichi Sankyo

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Edoxaban plasma levels on day 4 (edoxaban alone) and day 36 (edoxaban + tamoxifen). The following pharmacokinetic parameters will be taken: the lowest plasma concentration (C_{trough}), the maximum plasma concentration (C_{max}); time of maximum observed concentration (T_{max}). The area under the curve (AUC) over 24 hours will be calculated by Bayesian analysis by the collected 5 samples.

Toelichting onderzoek

Achtergrond van het onderzoek

Rationale: Edoxaban is an oral direct factor Xa inhibitor which is widely used in patients with venous thromboembolism (VTE) or non-valvular atrial fibrillation. Recently, this agent has been shown to be non-inferior to low-molecular-weight heparin (LMWH) to prevent recurrent VTE in cancer patients. Edoxaban is also a substrate for P-glycoprotein (P-gp), a protein that excretes certain xenobiotics into the urine, faeces, and bile. Tamoxifen, an anti-estrogen drug used as adjuvant treatment in breast cancer patients, is a known P-gp inhibitor. Therefore, concomitant use of tamoxifen can potentially increase plasma levels of edoxaban and thereby increase the risk of bleeding. In this study, the effect of tamoxifen on the pharmacokinetics of edoxaban will be evaluated.

Objective: To compare the plasma concentration of edoxaban in women with breast cancer before and during treatment with tamoxifen.

Study design: An open-label, single-sequence crossover study

Study population: Women with breast cancer and an indication for tamoxifen as adjuvant or palliative therapy.

Intervention: Twenty-six breast cancer patients who are scheduled for adjuvant or palliative treatment with tamoxifen, will be given edoxaban 60 mg once daily for 4 days. On day 5, edoxaban will be stopped and tamoxifen therapy started. When steady-state of tamoxifen is reached after 28 days, edoxaban 60 mg once daily is given for 4 days concomitantly with ongoing tamoxifen therapy. At the fourth day of both edoxaban treatment periods, 4 blood samples (at 0, 1, 2, and 3 hours after ingestion) and one blood sample randomly taken in the time period 4 – 8 hours after ingestion will be collected.

Main study parameters/endpoints: a comparison between day 4 and 36 of edoxaban area under the plasma concentration curve (AUC), maximum concentration (C_{max} and several other coagulation, pharmacokinetic and pharmacodynamic parameters.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will be seen in the hospital for inclusion and two times for a series of blood withdrawal on day 4 and 36. On days 4 and 36, patients have to be in the hospital for 4 hours. During these days, patients will get a venous cannula from which 4 blood samples will be taken per day over a time period of 3 hours. One sample will be obtained 4 to 8 hours after ingestion of edoxaban. Total volume of blood withdrawn is 54.6 ml per day. In this study, patients will use edoxaban, an anticoagulant drug. Patients may experience side effects of medication, such as hematomas. Based on previous studies with edoxaban, it is estimated that there is an individual risk of bleeding of 0.06% during this study. There is no individual benefit from participating in this study. However, the results may have clinical

impact, because in patients with breast cancer, tamoxifen is the mainstay of adjuvant treatment, often for a period of 5 years, where patients may suffer from VTE. Therefore, information on the safety of this combination is important.

Doel van het onderzoek

There is a minimal interaction between edoxaban and tamoxifen and it can safely be used concomitantly

Onderzoeksopzet

Day 4: blood samples after four days of edoxaban use

Day 36: blood samples after four days of edoxaban use concomitantly with tamoxifen after steady state is reached

Onderzoeksproduct en/of interventie

Twenty-six breast cancer patients who are scheduled for adjuvant or palliative treatment with tamoxifen, will be given edoxaban 60 mg once daily for 4 days. On day 5, edoxaban will be stopped and tamoxifen therapy started. When steady-state of tamoxifen is reached after 28 days, edoxaban 60 mg once daily is given for 4 days concomitantly with ongoing tamoxifen therapy. At the fourth day of both edoxaban treatment periods, 4 blood samples (at 0, 1, 2, and 3 hours after ingestion) and one blood sample randomly taken in the time period 4 – 8 hours after ingestion will be collected.

Contactpersonen

Publiek

Tergooi hospital/Amsterdam UMC, location AMC
Floris Bosch

+31 20 566 7050

Wetenschappelijk

Tergooi hospital/Amsterdam UMC, location AMC
Floris Bosch

+31 20 566 7050

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Age > 18 years
- Patients with oestrogen receptor positive breast cancer who are scheduled for adjuvant or palliative tamoxifen treatment

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Inability to provide informed consent
- Inherited bleeding disorder (e.g. von Willebrand disease)
- Major bleeding¹⁶ or clinically relevant non-major bleeding¹⁷ in the past 3 months (see appendix A)
- History of intracranial bleeding
- Gastric or duodenal ulcer in the past 5 years
- Uncontrolled blood pressure with systolic pressure >180 mmHg
- Use of antiplatelet or anticoagulant therapy
- Chronic NSAID use
- Major surgery in the past 3 weeks (surgery which penetrates and exposes a body cavity or produces substantial impairment of physical function)
- Pregnancy, puerperium, or current breast feeding
- Use of P-gp inhibitors or inducers and CYP3A4 inhibitors (see appendix B)
- Brain metastases
- Use of chemotherapy in the past 7 days or in the upcoming 32 days
- AST or ALT >3x of the upper limit in the past 7 days
- Liver cirrhosis Child Pugh A, B, or C
- Creatinine clearance of <50mL/min calculated with the Cockcroft and Gault formula in the past 7 days
- Body weight <60kg
- Platelet count <50,000/mL in the past 7 days

Onderzoeksopzet

Opzet

Type: Observationeel onderzoek, zonder invasieve metingen

Onderzoeksmodel:	Cross-over
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	30-09-2019
Aantal proefpersonen:	26
Type:	Verwachte startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nog niet bepaald

Ethische beoordeling

Positief advies	
Datum:	30-09-2019
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL8054

Register

Ander register

ID

METC AMC : METC 2018_328

Resultaten